Centessa Pharmaceuticals plc (NASDAQ:CNTA – Get Free Report) was the recipient of a significant growth in short interest during the month of September. As of September 30th, there was short interest totalling 1,960,000 shares, a growth of 30.7% from the September 15th total of 1,500,000 shares. Currently, 2.5% of the company’s shares are sold short. Based on an average daily trading volume, of 589,900 shares, the days-to-cover ratio is presently 3.3 days.
Centessa Pharmaceuticals Stock Down 3.4 %
Centessa Pharmaceuticals stock traded down $0.57 on Tuesday, hitting $16.09. 293,267 shares of the stock traded hands, compared to its average volume of 400,597. Centessa Pharmaceuticals has a 1 year low of $5.58 and a 1 year high of $17.59. The firm has a market cap of $1.62 billion, a P/E ratio of -11.33 and a beta of 1.46. The company has a current ratio of 13.29, a quick ratio of 13.29 and a debt-to-equity ratio of 0.27. The business’s fifty day simple moving average is $14.39 and its 200 day simple moving average is $11.25.
Centessa Pharmaceuticals (NASDAQ:CNTA – Get Free Report) last posted its quarterly earnings data on Tuesday, August 13th. The company reported ($0.40) EPS for the quarter, missing the consensus estimate of ($0.38) by ($0.02). As a group, sell-side analysts forecast that Centessa Pharmaceuticals will post -1.68 earnings per share for the current year.
Insider Activity
Institutional Trading of Centessa Pharmaceuticals
Several hedge funds and other institutional investors have recently made changes to their positions in the stock. GAMMA Investing LLC raised its stake in Centessa Pharmaceuticals by 103.1% during the third quarter. GAMMA Investing LLC now owns 2,972 shares of the company’s stock valued at $48,000 after buying an additional 1,509 shares during the last quarter. Quarry LP raised its position in shares of Centessa Pharmaceuticals by 47.8% in the 2nd quarter. Quarry LP now owns 9,608 shares of the company’s stock worth $87,000 after purchasing an additional 3,108 shares during the last quarter. China Universal Asset Management Co. Ltd. boosted its stake in Centessa Pharmaceuticals by 69.2% in the 1st quarter. China Universal Asset Management Co. Ltd. now owns 10,817 shares of the company’s stock worth $122,000 after purchasing an additional 4,423 shares in the last quarter. EntryPoint Capital LLC purchased a new stake in Centessa Pharmaceuticals during the 1st quarter valued at about $109,000. Finally, Sandia Investment Management LP bought a new stake in Centessa Pharmaceuticals during the 2nd quarter valued at about $90,000. Hedge funds and other institutional investors own 82.01% of the company’s stock.
Wall Street Analyst Weigh In
A number of research analysts recently issued reports on CNTA shares. Jefferies Financial Group boosted their price target on Centessa Pharmaceuticals from $13.00 to $19.00 and gave the company a “buy” rating in a report on Wednesday, September 11th. BMO Capital Markets upped their target price on Centessa Pharmaceuticals from $20.00 to $35.00 and gave the company an “outperform” rating in a report on Monday, September 16th. Guggenheim lifted their price target on shares of Centessa Pharmaceuticals from $20.00 to $24.00 and gave the company a “buy” rating in a report on Wednesday, September 11th. Morgan Stanley upgraded shares of Centessa Pharmaceuticals from an “equal weight” rating to an “overweight” rating and upped their price objective for the stock from $11.00 to $26.00 in a report on Thursday, September 19th. Finally, Oppenheimer reaffirmed an “outperform” rating and set a $14.00 target price on shares of Centessa Pharmaceuticals in a research note on Wednesday, August 14th. Six analysts have rated the stock with a buy rating, According to MarketBeat.com, Centessa Pharmaceuticals has an average rating of “Buy” and a consensus target price of $25.17.
Check Out Our Latest Report on Centessa Pharmaceuticals
Centessa Pharmaceuticals Company Profile
Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.
Read More
- Five stocks we like better than Centessa Pharmaceuticals
- Short Selling: How to Short a Stock
- Goldman Sachs Earnings Reveal Market Moves Investors Can’t Ignore
- Transportation Stocks Investing
- AMD Gains Momentum With AI: Can It Beat Expectations?
- High Dividend REITs: Are They an Ideal Way to Diversify?
- Lithium Grab: 2 Lithium Stocks That Could Be Takeover Targets
Receive News & Ratings for Centessa Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Centessa Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.